These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25117210)

  • 41. Impact of abdominal obesity and ambulatory blood pressure in the diagnosis of left ventricular hypertrophy in never treated hypertensives.
    Rodilla E; Costa JA; Martín J; González C; Pascual JM; Redon J
    Med Clin (Barc); 2014 Mar; 142(6):235-42. PubMed ID: 24139053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence and determinants of left ventricular hypertrophy and remodelling patterns in hypertensive patients: the St. Petersburg study.
    Conrady AO; Rudomanov OG; Zaharov DV; Krutikov AN; Vahrameeva NV; Yakovleva OI; Alexeeva NP; Shlyakhto EV
    Blood Press; 2004; 13(2):101-9. PubMed ID: 15182113
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relation of childhood risk factors to left ventricular hypertrophy (eccentric or concentric) in relatively young adulthood (from the Bogalusa Heart Study).
    Toprak A; Wang H; Chen W; Paul T; Srinivasan S; Berenson G
    Am J Cardiol; 2008 Jun; 101(11):1621-5. PubMed ID: 18489940
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.
    Palmieri V; Wachtell K; Gerdts E; Bella JN; Papademetriou V; Tuxen C; Nieminen MS; Dahlöf B; de Simone G; Devereux RB
    Am Heart J; 2001 May; 141(5):784-91. PubMed ID: 11320367
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Left ventricular filling abnormalities and obesity-associated hypertension: relationship with overproduction of circulating transforming growth factor beta1.
    Parrinello G; Licata A; Colomba D; Di Chiara T; Argano C; Bologna P; Corrao S; Avellone G; Scaglione R; Licata G
    J Hum Hypertens; 2005 Jul; 19(7):543-50. PubMed ID: 15944724
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of left-ventricular mass and remodeling in obese adolescents: M-mode, 2D or 3D echocardiography?
    Pacileo G; Castaldi B; Di Salvo G; Limongelli G; Rea A; D'Andrea A; Russo MG; Calabrò R
    J Cardiovasc Med (Hagerstown); 2013 Feb; 14(2):144-9. PubMed ID: 22343263
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of pericardial adipose tissue with left ventricular structure and function: a region-specific effect?
    Kim JS; Kim SW; Lee JS; Lee SK; Abbott R; Lee KY; Lim HE; Sung KC; Cho GY; Koh KK; Kim SH; Shin C; Kim SH
    Cardiovasc Diabetol; 2021 Jan; 20(1):26. PubMed ID: 33494780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronic high-fat diet-induced obesity decreased survival and increased hypertrophy of rats with experimental eccentric hypertrophy from chronic aortic regurgitation.
    Dhahri W; Drolet MC; Roussel E; Couet J; Arsenault M
    BMC Cardiovasc Disord; 2014 Sep; 14():123. PubMed ID: 25249193
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance.
    Chirinos JA; Segers P; De Buyzere ML; Kronmal RA; Raja MW; De Bacquer D; Claessens T; Gillebert TC; St John-Sutton M; Rietzschel ER
    Hypertension; 2010 Jul; 56(1):91-8. PubMed ID: 20458004
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hemodynamic overload and intra-abdominal adiposity in obese children: Relationships with cardiovascular structure and function.
    Kozakova M; Morizzo C; Bianchi V; Marchetti S; Federico G; Palombo C
    Nutr Metab Cardiovasc Dis; 2016 Jan; 26(1):60-6. PubMed ID: 26643211
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alterations in cardiac structure and function in hypertension.
    Santos M; Shah AM
    Curr Hypertens Rep; 2014 May; 16(5):428. PubMed ID: 24639061
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension.
    Muscholl MW; Schunkert H; Muders F; Elsner D; Kuch B; Hense HW; Riegger GA
    Am Heart J; 1998 Jan; 135(1):58-66. PubMed ID: 9453522
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Subclassification of left ventricular hypertrophy based on dilation stratifies coronary artery disease patients with distinct risk.
    Huang BT; Peng Y; Liu W; Zhang C; Huang FY; Wang PJ; Zuo ZL; Liao YB; Chai H; Li Q; Zhao ZG; Luo XL; Ren X; Huang KS; Meng QT; Chen C; Huang DJ; Chen M
    Eur J Clin Invest; 2014 Oct; 44(10):893-901. PubMed ID: 25104141
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: is the difference limited to obese hypertensives?
    Cuspidi C; Meani S; Negri F; Giudici V; Valerio C; Sala C; Zanchetti A; Mancia G
    J Hum Hypertens; 2009 Nov; 23(11):728-34. PubMed ID: 19322202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Obesity and heart failure.
    De Pergola G; Nardecchia A; Giagulli VA; Triggiani V; Guastamacchia E; Minischetti MC; Silvestris F
    Endocr Metab Immune Disord Drug Targets; 2013 Mar; 13(1):51-7. PubMed ID: 23369137
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The relationship between left ventricular deformation and different geometric patterns according to the updated classification: findings from the hypertensive population.
    Tadic M; Cuspidi C; Majstorovic A; Kocijancic V; Celic V
    J Hypertens; 2015 Sep; 33(9):1954-61; discussion 1961. PubMed ID: 26002842
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of hypertension with or without diabetes on left ventricular remodeling in rural Chinese population: a cross-sectional study.
    Li T; Chen S; Guo X; Yang J; Sun Y
    BMC Cardiovasc Disord; 2017 Jul; 17(1):206. PubMed ID: 28750662
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
    Devereux RB; Palmieri V; Liu JE; Wachtell K; Bella JN; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
    J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High Normal Blood Pressure and Left Ventricular Hypertrophy Echocardiographic Findings From the PAMELA Population.
    Cuspidi C; Facchetti R; Bombelli M; Tadic M; Sala C; Grassi G; Mancia G
    Hypertension; 2019 Mar; 73(3):612-619. PubMed ID: 30612493
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).
    Pouleur AC; Anker S; Brito D; Brosteanu O; Hasenclever D; Casadei B; Edelmann F; Filippatos G; Gruson D; Ikonomidis I; Lhommel R; Mahmod M; Neubauer S; Persu A; Gerber BL; Piechnik S; Pieske B; Pieske-Kraigher E; Pinto F; Ponikowski P; Senni M; Trochu JN; Van Overstraeten N; Wachter R; Balligand JL
    ESC Heart Fail; 2018 Oct; 5(5):830-841. PubMed ID: 29932311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.